GENMAB A/S (GMXAY)
GMXAY moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How GMXAY actually reacts to news — the realized, point-in-time move the market made, measured across 125 labeled events over its full measured history with zero look-ahead.
GMXAY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 26% | 84 |
| 30-min | 0.00% | 38% | 96 |
| 60-min | 0.00% | 41% | 100 |
| to close | 0.00% | 48% | 120 |
| Middle 50% of GMXAY reactions | -0.01% to +0.26% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 125 |
Half of all GENMAB A/S news events land between -0.01% and +0.26% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GMXAY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GMXAY's baseline. Nothing else.
Recent GMXAY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K GENMAB A/S For: Oct 13 | SEC filing · Form 6-K | SEC EDGAR | +0.07% | -1.77% | |
| Form 6-K GENMAB A/S For: Oct 07 | SEC filing · Form 6-K | SEC EDGAR | -0.12% | -2.17% | |
| Form 6-K GENMAB A/S For: Oct 05 | SEC filing · Form 6-K | SEC EDGAR | -0.58% | -2.11% | |
| Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma | Press release | GlobeNewswire | +9.35% | +7.23% | |
| Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer | Press release | Business Wire | +0.85% | +9.63% | |
| Form 6-K GENMAB A/S For: Oct 02 | SEC filing · Form 6-K | SEC EDGAR | +0.19% | +1.86% | |
| Form 6-K GENMAB A/S For: Sep 29 | SEC filing · Form 6-K | SEC EDGAR | +0.34% | +1.77% | |
| Form 6-K GENMAB A/S For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | +0.23% | -0.30% | |
| Form 6-K GENMAB A/S For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | +0.22% | -1.28% | |
| Form 6-K GENMAB A/S For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.90% | |
| Form 6-K GENMAB A/S For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | -0.65% | -0.47% | |
| Form 6-K GENMAB A/S For: Aug 12 | SEC filing · Form 6-K | SEC EDGAR | +0.19% | +0.96% | |
| Form 6-K GENMAB A/S For: Aug 11 | SEC filing · Form 6-K | SEC EDGAR | -0.08% | +0.07% | |
| Form 6-K GENMAB A/S For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.24% | +1.74% | |
| Form 6-K GENMAB A/S For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | -0.83% | +0.21% | |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026 | Press release | GlobeNewswire | -0.83% | +0.21% | |
| Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma | Press release | Business Wire | +0.66% | -0.43% | |
| Form 6-K GENMAB A/S For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | -0.27% | -1.75% | |
| Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival | Press release | GlobeNewswire | -0.27% | -1.75% | |
| Form 6-K GENMAB A/S For: Jun 17 | SEC filing · Form 6-K | SEC EDGAR | +0.20% | -0.90% | |
| Form 6-K GENMAB A/S For: Jun 16 | SEC filing · Form 6-K | SEC EDGAR | -0.12% | +0.75% | |
| Form 6-K GENMAB A/S For: Jun 15 | SEC filing · Form 6-K | SEC EDGAR | -0.20% | -0.81% | |
| Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | Press release | Business Wire | -1.23% | -2.23% | |
| Form 6-K GENMAB A/S For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | -0.36% | +0.12% | |
| Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients | Press release | Business Wire | +0.16% | +0.68% | |
| Form 6-K GENMAB A/S For: May 29 | SEC filing · Form 6-K | SEC EDGAR | -0.08% | -1.20% | |
| Form 6-K GENMAB A/S For: May 13 | SEC filing · Form 6-K | SEC EDGAR | -0.02% | +0.24% | |
| Major Shareholder Announcement | Press release | GlobeNewswire | +0.04% | +1.26% | |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 | Press release | GlobeNewswire | +1.66% | +0.48% | |
| Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | Press release | Business Wire | -0.07% | +0.39% | |
| Major Shareholder Announcement | Press release | GlobeNewswire | +0.62% | -0.04% | |
| Major Shareholder Announcement | Press release | GlobeNewswire | -0.33% | -0.69% | |
| Genmab Publishes 2025 Annual Report | Press release | GlobeNewswire | -0.11% | -2.65% | |
| Genmab Portfolio Prioritization Update | Press release | GlobeNewswire | -0.24% | -1.13% | |
| Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period | Press release | GlobeNewswire | -0.22% | -1.57% | |
| Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R²) in Patients with Relapsed or Refractory Follicular Lymphoma | Press release | Business Wire | +0.20% | -0.25% | |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | Press release | GlobeNewswire | +0.00% | +0.49% | |
| Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma | Press release | GlobeNewswire | -0.23% | +1.57% | |
| Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer | Press release | Business Wire | -0.81% | -3.05% | |
| Genmab Announces Financial Results for the First Half of 2025 | Press release | GlobeNewswire | +0.69% | +0.29% | |
| Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) | Press release | GlobeNewswire | +2.73% | +3.30% | |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 | Press release | GlobeNewswire | +0.70% | +2.01% | |
| Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) | Press release | Business Wire | -0.65% | -0.44% | |
| Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial | Press release | Business Wire | -0.25% | -0.37% | |
| Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress | Press release | Business Wire | -0.10% | -1.80% | |
| Genmab Announces Financial Results for the First Quarter of 2024 | Press release | GlobeNewswire | +0.28% | -0.08% | |
| Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R²) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) | Press release | Business Wire | -0.23% | -0.51% | |
| New Chromatography Data Platform Wins Bio-IT World Award for Genmab and Genedata | Press release | PR Web | -0.05% | -2.18% | |
| TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer | Press release | Business Wire | +0.10% | +0.56% | |
| TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy | Press release | Business Wire | +0.45% | +1.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GMXAY section they belong to.
Where else GMXAY is measured.
GMXAY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Synergy CHC Corp. (SNYR) | 126 | -0.06% | 43% |
| Accelerate Diagnostics, Inc. (AXDX) | 125 | -0.16% | 36% |
| BIOTRICITY INC (BTCY) | 124 | 0.00% | 38% |
| CLEMENTIA PHARMACEUTICALS INC COMMON SHARES (CMTA) | 124 | +0.03% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is GENMAB A/S's median reaction calculated?
Every labeled GMXAY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 125 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 38% of GMXAY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GMXAY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.